Nov. 3, 2015
"We achieved positive pre-clinical animal data for pulmonary hypertension, initial echocardiography and neurohormonal clinical data pointing to neuromodulation as a mechanism for potential myocardial recovery"
"The Company conducted a pre-clinical pulmonary artery hypertension study at Jewish Hospital in Louisville, Kentucky under the guidance of Dr. Mark Slaughter. This acute animal study demonstrated a profound impact in reducing pulmonary hypertension in the animals. Additional pre-clinical studies are planned in the fourth quarter of 2015."
No mention in 4 th quarter release Mar 3, 2016 , does this mean they have stopped this study due to funding or it failed.
- Forums
- ASX - By Stock
- SHC
- Pulmonary Hypertension
Pulmonary Hypertension
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)